EVAC completed its initial public offering in July 2025, with dramatic balance sheet expansion and the forfeiture of 575,000 founder shares when the underwriters' over-allotment option expired unexercised.
This represents EVAC's transition from pre-revenue startup to public company status, with $465.7M in assets primarily held in trust for future acquisitions. The forfeiture of founder shares due to incomplete over-allotment exercise suggests less-than-optimal demand for the IPO, which could indicate market skepticism about the company's prospects or valuation.
EVAC's financials reflect a classic SPAC structure post-IPO, with total assets surging 35,927% to $465.7M primarily from IPO proceeds held in trust, while stockholders' equity became deeply negative at -$16.1M due to the SPAC's structural mechanics. Despite showing positive net income of $4.4M (likely from trust account investment income), operating income remains negative at -$354K and operating cash flow deteriorated to -$508K, indicating the company is still burning cash on operations while the bulk of IPO proceeds sit in trust awaiting a business combination.
Asset base grew 35926.7% — expansion through organic growth, acquisitions, or capital deployment.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Cash position surged 14375.7% — strong cash generation or capital raise providing significant financial cushion.
Current assets grew 12032.6% — improving short-term liquidity or inventory/receivables build.
Net income grew 9035.3% — bottom-line growth signals improving overall business health.
Operating cash flow fell 1330.3% — earnings quality concerns; investigate working capital changes and non-cash items.
Liabilities grew 1213% — significant increase in debt or obligations, assess impact on financial flexibility.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Current liabilities reduced — improved short-term financial position and working capital health.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →